HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eicosapentaenoic Acid (EPA) Decreases the All-Cause Mortality in Hemodialysis Patients.

AbstractOBJECTIVE:
Atherosclerosis, which causes cardiovascular disease, is a major cause of death in hemodialysis (HD) patients. Eicosapentaenoic acid (EPA), an anti-hyperlipidemic agent, is known to have antioxidative or anti-inflammatory effects, resulting in improvements in atherosclerosis. In the present study, we examined whether EPA improves the all-cause mortality in patients receiving regular HD therapy.
METHODS:
We enrolled 176 patients treated with maintenance HD therapy and performed a longitudinal observational cohort study for three years. We divided the patients into two groups based on whether or not the received EPA treatment [EPA(+) and EPA(-), respectively]. The primary end-point was all-cause death. We also matched the two groups using propensity score matching and examined the effect of EPA.
RESULTS:
Before matching, the all-cause mortality rates were 24.0% in the EPA(+) and 11.8% in the EPA(-) groups, which were significantly different (p=0.044). After propensity score matching, the EPA(+) group still showed a significantly better prognosis than the EPA(-) group (p=0.038). A multivariate analysis showed that EPA treatment significantly reduced the risk of all-cause mortality both before and after propensity score matching.
CONCLUSION:
EPA treatment is independently associated with lower mortality in HD patients.
AuthorsTomoko Inoue, Kazuhiro Okano, Yuki Tsuruta, Yukio Tsuruta, Ken Tsuchiya, Takashi Akiba, Kosaku Nitta
JournalInternal medicine (Tokyo, Japan) (Intern Med) Vol. 54 Issue 24 Pg. 3133-7 ( 2015) ISSN: 1349-7235 [Electronic] Japan
PMID26666599 (Publication Type: Journal Article, Observational Study)
Chemical References
  • Eicosapentaenoic Acid
Topics
  • Atherosclerosis (mortality, physiopathology)
  • Cause of Death
  • Eicosapentaenoic Acid (administration & dosage)
  • Female
  • Humans
  • Kidney Failure, Chronic (mortality, physiopathology, therapy)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prognosis
  • Renal Dialysis (adverse effects)
  • Risk

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: